News

Article

Guidance on Q13 Continuous Manufacturing of Drug Substances and Drug Products

Author(s):

The guidance is intended to build on the existing International Council for Harmonisation (ICH) quality guidance.

A new industry guidance, Q13 Continuous Manufacturing of Drug Substances and Drug Products, issued in March 2023 by FDA, explains the scientific and regulatory considerations for the development, implementation, operation, and lifecycle management of continuous manufacturing (CM). The guidance is intended to build on the existing International Council for Harmonisation (ICH) quality guidance and to provide clarification on CM concepts while further describing scientific approaches and regulatory considerations specific to CM of drug substances and drug products.

Further, the guidance applies to CM of drug substances and drug products for chemical entities and therapeutic proteins. It can be applicable to CM for new products, such as new drugs, generic drugs, and biosimilars, and for the conversion of batch manufacturing to CM for existing products.

Source: FDA

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Related Content